New Delhi, Nov. 12 (LTI) firm Lupin received a report from the US Health Regulatory Authority on Monday inspecting his Nagpur facility.
"The United States Food and Drug Administration (USFDA) has conducted a pre-approved review of the 100 mg capsule of phenytoin sodium," Lupine told BSE.
The plant was tested by USFDA in September 2018.
USFDA will provide EDA with a FDA or FDA closure inspection facility.
Lupine Nilesh Gupta: "Successful completion of Nagpur Inspection is optimal development, as we meet international standards and exceed it." Lupine's shares today were 1.64% higher on Rs at 868.20 tenge on BSE.
This is a public announcement from the PTI channel.